BioPharmX

BioPharmX Corporation (NYSE American: BPMX) is a specialty pharmaceutical company focused on developing products that treat chronic dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal. The Company is developing prescription products through its proprietary HyantX™ delivery system for dermatology indications. BioPharmX has two lead products in development, BPX-04 for the treatment of papulopustular rosacea and BPX-01 for the treatment of acne vulgaris.

Ravgen

Specializing in non-invasive prenatal genetic testing and paternity testing, Ravgen is focused on developing non-invasive prenatal diagnostic tests based on fetal DNA present in maternal blood. Diagnose single gene disorders, such as cystic fibrosis, sickle cell anemia and Downs syndrome, establish paternity and more early on in pregnancy.

Prolexys Pharmaceuticals

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include a) solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) the colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. Prolexys' ability to identify and validate novel therapeutic targets is driven by its technological leadership in the field of proteomics and the application of proteomics technologies to its own, and its partners, drug discovery programs. Prolexys has developed two key technologies, a high throughput yeast 2 hybrid system called HyNet™, and a mass spectrometry-based protein science technology called HySpec™, that complement one another and provide a powerful approach for identifying novel molecular targets relevant to the treatment of human disease. In addition, Prolexys has developed HyScreen, to validate the therapeutic utility of these novel targets as well as in house high-throughput screening, in vivo pharmacology, medicinal chemistry, and drug development capabilities. Prolexys was formed in 2001 with investments from Myriad Genetics, Inc., Hitachi Ltd., Friedli Corporate Finance, A.G., and Oracle Corporation. The company is privately held and located in Salt Lake City, Utah.

Sapere Bio, Inc

Sapere Bio is a diagnostic company in a clinical stage of development. We measure signatures of aging which are then developed into clinical risk prediction tools to predict patient's risk for adverse events in cardiology, nephrology, oncology, and neurology. Our highly differentiable products address critical and unmet medical need and allow risk, inherent to the patient, to be quantified. Accurate risk stratification before procedures and therapies will improve patients' quality of life, decrease disability and mortality, and cut healthcare costs. Sapere Bio was co-founded by Dr. Norman Sharpless at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine-Chapel Hill and Dr Natalia Mitin, current CEO of Sapere Bio.

INDESEEM, INC.

INDESEEM, Inc. was established on the 13th day of December 2013 and was incorporated in the Commonwealth of Massachusetts on the 5th day of December 2017 as a nonprofit educational, research, and development organization working with partners and stakeholders in developing and least developed countries. INDESEEM, Inc. provides technical and non-technical services to our partners and stakeholders working in developing and least developed countries to collaboratively achieve the United Nations Sustainable Development Goals by 2030 and beyond. Our team of expert provides technical solutions in the fields of education, agricultural research and development, environment and climate change, sustainability, positive youth development, global and public health, community development planning and public policy, energy and water security. The non-technical services include applied research design and implementation, desk research, project design and collaborative implementation, monitoring and evaluation, marketing trends research and analysis, technology for rural communities in developing countries, sustainability modeling, geospatial analysis, mapping, and visualization. We are a public benefit corporation and meets all legal requirements and compliance. Our works focus on impacting 8 major thematic areas in connections with the United Nations Sustainable Development Goals: 1. Ensuring Sustainability 2. Protecting the Environment and Climate 3. Improving Agriculture and Food Systems 4. Reducing Poverty and Inequality 5. Advancing Health and Sanitation 6. Assisting Forced Migrants 7. Supporting Community-led Social Business 8. Enhancing Information Communications Technology (ICT) in developing countries.